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.2012.02.Abstract Background: Hepatectomy elaborates signiﬁcant post-operative pain. Opioids represent
cornerstone for post-operative analgesia in such cases. This study examined the therapeutic effect
and outcome of adding low dose ketorolac tromethamine infusion to PO intravenous patient con-
trolled fentanyl analgesia IV-PCA.
Patients and methods: Sixty right lobe donors were randomized into either fentanyl or ketorolac
groups (30 patients each). Patients in both groups received fentanyl (2 lg/ml) solution in normal
saline as IV-PCA with background infusion in a rate adjusted to deliver 0.25 lg kg h1 and boluses
of 10 ml with a lock-out time of 20 min. They received 15 mg ketorolac IV bolus in ketorolac group
and similar placebo injection in the control. Patients in both groups received a continuous intrave-
nous infusion of 240 ml normal saline solution that is either free in the FENT group or containing
60 mg ketorolac in ketorolac group, adjusted to a rate of 0.2 ml kg h1. Visual analogue scorepartment of Anesthesia and
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.
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200 A.M. Yassen, G.E. Sayed(VAS) and hemodynamic proﬁle were recorded at 1, 6, 12, 24, 36 and 48 h while laboratory results
were recorded after 48 h and 7 days post-operatively.
Results: VAS was signiﬁcantly lower in ketorolac group compared to fentanyl group from 6 to 36 h
post-operatively while sedation scorewas signiﬁcantly higher in fentanyl group compared to fentanyl–
ketorolac group between 12 and 36 h post-operatively. Fentanyl consumption was signiﬁcantly lower
in ketorolac group at 24 (318.7 ± 66 vs 468.3 ± 79) and 48 (211.5 ± 59 vs 369.1 ± 68) h. Hemody-
namic data and laboratory parameters were comparable in both groups. Nausea had a signiﬁcantly
higher incidence in FENT compared toKETR groups while other complications (vomiting and blood
loss) were homogenous in both groups.
Conclusion: Adding ketorolac to IV PCA fentanyl improved the analgesic state and reduced the dose
of fentanyl usedwithout adding any side effects or risks to donors subjected to right lobe hepatectomy.
ª 2012 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Post-operative pain constitutes a major problem for patients
after major abdominal surgery. Several modalities have been
investigated; yet, consensus about an ideal protocol has never
been reached. Liver resections mandates grave attention to
post-operative analgesia protocol due to both large abdominal
incision and the derangements on the drug pharmacokinetics
ensued by major hepatic tissue resection. Epidural analgesia
is a commonly used modality for post-operative pain manage-
ment after liver resection [1]. However, the risk of epidural
hematoma renders its use in those patients questionable and
is often avoided [2].
Cywinski et al. used thoracic patient controlled epidural
analgesia (PCEA) in right lobe resection for living liver dona-
tion and tumor resection. They found that patients subjected
to right lobe liver resection for liver donation experienced signif-
icant post-operative pain compared to patients who had resec-
tion for malignancy. Additional factors were postulated to
explain the predisposition of the right lobe liver donors to aug-
mented post-operative pain perception [3]. Previous investiga-
tors demonstrated superiority of the epidurally administered
opioids compared to intravenous rout using PCA technique in
both [4,5]. Hence, Modiﬁcations in the IV PCA technique are
required to enhance its activity to match the epidural rout.
Opioid analgesia, especially in high doses has many side ef-
fects as nausea, vomiting, pruritus, urinary retention, delayed
bowel movement and respiratory depression which limit its
use. The association of non-steroidal anti-inﬂammatory drugs
(NSAIDs) with opioid is effective in postoperative analgesia,
and can reduce the side effects due to opioid sparing effect
[6]. Ketorolac tromethamine is a NSAID with a potent analge-
sic efﬁcacy. While NSAIDs are always blamed for increasing
bleeding tendency [7], lowering the dose of the NSAIDs may
be of prime favorable impact on reducing this side effect. So,
in this work, we tested the hypothesis that a low dose of ketor-
olac administered via IV infusion will synergistically add to the
analgesic effect of PCA fentanyl without adding morbidity to
patients after major hepatectomy. Pain assessed via visual ana-
logue score was the primary outcome parameter in this trial.
2. Patients and methods
After approval of the relevant ethical committee and obtaining
informed consent, 60 patients scheduled for right lobe hepatec-
tomy for right lobe liver donation in Mansoura gastroenterol-ogy surgical centre – liver transplantation program were
enrolled in this randomized double-blind controlled trial. Inclu-
sion criteria included patients between 21 and 40 years old and
right hepatectomy. Patients receiving non-steroidal anti-inﬂam-
matory drugs, anti-platelets or neuro-active or antipsychotic
drugs and patients with history of recurrent hyperacidity or gas-
tritis were excluded from the study. All patients were anaesthe-
tized by the same anesthesia team using a standard anesthesia
protocol. Anesthesia induction was achieved by intravenous
injection of propofol 1 mg kg1 and fentanyl 1 lg kg1 and
endotracheal intubation was facilitated by rocuronium bromide
0.3 mg kg1. Anesthesia was maintained by sevoﬂurane in oxy-
gen/air mixture (40%) and fentanyl infusion 1 lg kg h1 that
was discontinued at peritoneal closure. Patients were extubated
in the operating theater and transported to the intensive care
unit (ICU). Upon admission to the ICU, patients were random-
ized into one of two groups based on the analgesic regimen
using closed envelopes containing a randomly generated se-
quence of numbers pre allocated to the two groups. Fentanyl
group (FENT) represented the control groups and fenta-
nyl + Ketorolac group (KETR) represented the treatment
group and each group included 30 patients who were all in-
structed about the proper use of the PCA pre-operatively and
again at admission to the ICU. In both groups, analgesia was
achieved via fentanyl using patient controlled intravenous anal-
gesia (PCA). Fentanyl 500 lg were diluted in 250 cc normal sal-
ine to have a concentration of 2 lg ml and was attached to PCA
pump (LifeCare 4100 PCA II system, by Abbott medical sys-
tems, USA). Background infusion was adjusted at a dose of
0.25 lg kg h1 commenced while the Push up bolus doses were
adjusted to give 10 mls of the solution (20 lg) and lock-out
interval was adjusted to 20 min. Another solution was prepared
containing either 240 ml normal saline (placebo) or 60 mg of
ketorolac in 240 ml saline (concentration of 250 lg ml) and
the solution was infused continuously in a rate of 0.2 ml kg h
1 to deliver a dose of 50 lg kg h1 of ketorolac. Patients in fen-
tanyl group (FENT) received a single injection of 100 ml nor-
mal saline (placebo) intravenously over 30 min while in
ketorolac group (KETR), patients received a single injection
of 15 mg of ketorolac in 100 ml normal saline intravenously
over 30 min. All infusions continued for 48 h. Both the patient
and the physician assessing the pain score and hemodynamic
data were unaware of the infused solutions. Visual analogue
score (VAS) was assessed at 1, 6, 12, 24, 36 and 48 h (at rest)
using a standard VAS ruler (0–10) and sedation was simulta-
neously assessed by RAMSY(8) sedation score (6 points score)
Assessed for eligibility (n=73) 
Not meeting inclusion criteria (n=13) 
Randomized (n=60) 
Allocated to FENT (n=30) Allocated to KETR (n=30) 
Excluded (n=1 ) 
Case 8: Reoperation 
Analyzed (n=29) 
Excluded (n=2 ) 
Case 32: Protocol Violation - UN 
blinding 
Case 41: Reoperation 
Analyzed (n=28) 
Figure 1 CONSORT chart.
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were assessed on a binary scale (Present/Absent) and were pre-
sented as incidence (%). Hemodynamic data were recorded at
the same time points with VAS. Laboratory assessment was per-
formed in the morning of the third and seventh post-operative
days. Bleeding time was assessed using Duke’s technique and
blood loss was calculated from the abdominal drains plus any
signiﬁcant soaking of the dressing. Total amount of fentanyl gi-
ven was recorded at 24 and 48 h. The primary outcome objec-
tive of this trial is the 24th hour VAS while secondary
objectives included daily fentanyl doses, degree of analgesia,
hemodynamic proﬁle, laboratory proﬁles and complications.
2.1. Statistical analysis
The primary outcome objective in this trial was VAS. For sam-
ple size determination, the 24th hour value was used for effect
size. A priori power study was performed to detect an effect
size of 20% and alpha error or 0.05% to acquire 90% power.
26 cases per group were required to achieve the designated
power yet, 30 patients were enrolled in every group for com-
pensating for probable withdrawals and disqualiﬁcations.
Continuous data were tested for normality using kolmo-
grove–smirnove test and all exhibited normal distribution
and were presented as mean ± SD. Differences between
groups were tested using two-tailed independent sample t test
(equal variance assumed). Interval data and total fentanyl
doses were tested for signiﬁcant difference between groups
using Mann-Whitney U test. Incidence of nausea and vomiting
was compared using Chi square. Statistical signiﬁcance was as-
sumed when P is less than or equal to 0.05 and analysis was
performed using Statistical package for social sciences (SPSS)
ver 14.USA.3. Results
The study recruited 60 patients who were randomized into
either fentanyl or fentanyl + ketorolac groups. 30 patients were
enrolled in each group. Out of them 29 patients completed the
protocol in FENT group while 1 patient was excluded during
the study period due to revision operation (patient 8). In KETR
group, 28 patients completed the protocol while one case was
excluded due to surgical revision and another case for protocol
violation (Unblinding) (patient 32) (Fig. 1). Neither patient
characteristics nor operative data showed any signiﬁcant differ-
ences between the studied groups (Table 1). Day three hemoglo-
bin, ICU blood loss and ICU stay were homogenous among
both groups (Table 1). Table 2 demonstrates MAP, HR and
RR for the studied groups and showed no signiﬁcant differences
in these parameters among patients in both groups. Visual ana-
logue score was signiﬁcantly lower inKETR group compared to
similar values in FENT group starting from 6 h reading until
36 h readings while sedation score was signiﬁcantly higher in
the FENT group compared to the KETR group from 12 to
36 h post-operatively (Fig. 2). Meanwhile, the Daily doses of
fentanyl were signiﬁcantly lower in KETR group compared to
FENT group at 24 h (318.7 ± 66 lg vs 468.3 ± 79 lg,
P= 0.013, CI = (11.50–92.13) and 48 h (211.5 ± 59 lg vs
369.1 ± 68 lg, P= 0.001, CI = (70.45–112.56) (Fig. 3). Out-
come parameters included liver functions, renal functions and
coagulation proﬁle. Neither of these outcome parametersdemonstrated signiﬁcant difference between both groups both
at 3rd and 7th PO days (Table 3). Nausea was signiﬁcantly more
frequent in the FENT group compared to KETR group (58.62
vs 21.42, P= 0.021) while vomiting, and blood loss did not dif-
fer signiﬁcantly among the studies groups (Table 4).
4. Discussion
This trial evaluated the analgesic efﬁcacy of adding low dose of
ketorolac tromethamine continuous intravenous infusion to IV
PCA fentanyl after right lobe donor hepatectomy and found
that the addition of ketorolac to IV PCA fantanyl achieved
better analgesia, better patients alertness and reduced the inci-
dence of nausea in this sensitive patient group without adding
any morbidity.
Intravenous patient controlled analgesia give good analge-
sia and patient satisfaction by allowing the patients to control
their pain [9,10]. In this study, patients receiving both IV PCA
fentanyl and IV infusion of Ketorolac experienced less pain ex-
pressed as a signiﬁcantly lower visual analogue score compared
to patients receiving IV PCA fentanyl only from 6 to 36 h post-
operatively. IV-PCA using both opioids and NSAIDs is a
common method for acute post-operative pain management.
The synergism between NSAIDs working primarily via modu-
lation of arachidonic acid cascade at peripheral sites with opi-
oids that act mainly centrally on speciﬁc receptors is effective
in different types of surgery [11,12]. Na et al concluded that
IV-PCA with fentanyl and ketorolac provides satisfactory
and safe posto-perative analgesia after craniotomy [13].
In our trial, we investigated right lobe liver donors who
share common characteristic features that inﬂuence drug phar-
Table 1 Patients characteristics: Data are in mean ± SD, number (range) or ratio.
FENT group KETR group P value
Age (years) 28.24 ± 5.2 30.18 ± 4.9 0.166
Sex (M/F) 24/5 26/2 0.348
BMI 21.2 ± 2.1 22.3 ± 1.9 0.094
Operative duration (min) 273.6 ± 56 301.7 ± 69 0.231
Intraoperative fentanyl (Ug) 463 ± 105 415 ± 97 0.524
ICU stay number (Range) 2(2–3) 2(2–3) 0.92
Platelets 303.3 ± 56.3 295.5 ± 45.9 0.073
Admission Hg 12.45 ± 1.1 12.3 ± 1.3 0.064
Day 3 Hg 11.8 ± 1.1 11.4 ± 1.2 0.311
IO blood product transfusion 0 0 –
Remaining liver volume (%) 37.4 ± 3.1 36.3 ± 2.9 0.427
BMI = body mass index, Hg = hemoglobin and IO = intra-operative.
Table 2 Hemodynamic data of FENT group (n= 29) and KETR group (n= 28): Data are in mean ± SD.
Heart rate P Mean arterial pressure P Respiratory rate P
FENT group KETR group FENT group KETR group FENT group KETR group
1 h PO 87.3 ± 4.5 85.5 ± 6.8 0.214 85.5 ± 3.8 86.3 ± 2.8 0.344 20 ± 3.1 21 ± 3.3 0.748
6 h PO 85.3 ± 4.2 82.3 ± 6.1 0.425 90.8 ± 4.8 93.3 ± 5.6 0.056 19.2 ± 2.5 20.2 ± 1.0 0.453
12 PO 81.7 ± 4.1 80.3 ± 3.7 0.061 89.8 ± 5.2 88.7 ± 5.3 0.741 17.3 ± 1.9 19.0 ± 2.5 0.081
24 h PO 78.8 ± 4.7 79.2 ± 5.4 0.121 82.5 ± 5.7 86.2 ± 5.5 0.455 15.3 ± 1.6 14.8 ± 1.9 0.132
36 h PO 79.5 ± 5.3 80.3 ± 4.5 0.072 88.2 ± 4.8 87.2 ± 5.0 0.059 14.3 ± 1 14.2 ± 1.2 0.063
48 h PO 78.5 ± 3.9 79.0 ± 3.5 0.278 79.8 ± 1.5 82.2 ± 6.1 0.521 14.0 ± 1.8 13.5 ± 1.5 0.547
PO= Post-operative.
Figure 2 Visual analogue score and sedation score for the
studied groups. *Signiﬁcant compared to Fentanyl group.
Figure 3 Fentanyl used in the study groups during the study
period.*Signiﬁcant compared to Fentanyl group.
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usually resected reducing their metabolic capacity of the liver
especially for drugs which are primarily metabolized through
the liver like Ketorolac [14]. Second, those patients almost al-
ways receive no blood product transfusion for fear of transfu-
sion acquired infections, hence, blood loss is always replaced
by ﬂuids reducing the circulating quantity of plasma proteins
and diluting the already existing amount. Drugs that are exten-
sively pound to plasma proteins like ketorolac will subse-
quently have a more free active percentage of the drug in the
circulation [14]. These two elements justiﬁed the use of a lower
dose of ketorolac in this patient category compared to the
standard dosage recommended in other post-operative settings[15] Our ﬁndings supported these assumptions since an appre-
ciably low dose of ketorolac infusion (50 lg kg h1) could
achieve the desired analgesic target. Both groups exhibited a
difference between them after 6 h from starting the infusion,
a time that was required to build up a sufﬁcient trough level
of ketorolac in the plasma after a reduced bolus dose of
15 mg given initially to this group that could not initiate a sta-
tistically signiﬁcant difference with the control group in this
early phase with maximum pain. Meanwhile, at 48 h, patients
in both groups had a satisfactory analgesia. A ﬁnding that
points mainly to the build up of a sufﬁcient analgesic barrier
by fentanyl alone fortiﬁed by the chronologically induced
reduction of pain intensity after 48 h from surgery.
Table 3 Outcome parameters (liver functions, coagulation proﬁle, renal functions and blood loss)data of FENT group (n= 29) and
KETR group (n= 28) at post-operative day 3 and day 7: Data are in mean ± SD.
FENT group KETR group Diﬀerence (95% CI)
Day 3 Lab. results
S. Bilirubin 2.05 ± 0.76 1.85 ± 0.50 0.20 (0.63 to 1.03)
ALT 187.8 ± 85.92 173.7 ± 32.8 14.17 (69.49 to 97.83)
PC 66.0 ± 7.9 68.5 ± 8.1 2.5 (12.77 to 7.77)
INR 1.6 ± 0.37 1.6 ± 0.23 0.02 (0.41 to 0.38)
Bleeding time 3.2 ± 1.4 3.5 ± 1.9 0.30 (1.10 to 0.96)
Factor V 57.0 ± 7.3 61.2 ± 9.6 4.20 (15.10 to 1.23)
aPTT 46.5 ± 7.0 47.5 ± 6.2 1.0 (9.54 to 7.44)
S. Createnine 1.0 ± 0.14 0.95 ± 0.16 0.05 (0.15 to 0.25)
Blood urea 28.0 ± 3.58 26.5 ± 5.43 1.50 (4.42 to 7.24)
Day 7 Lab. results
S. Bilirubin 1.17 ± 0.12 1.7 ± 0.23 0.00 (0.23 to 0.24)
ALT 69.7 ± 32.4 58.2 ± 26.8 11.5 (21.4 to 16.8)
PC 83.5 ± 6.7 85.4 ± 6.0 1.83 (9.9 to 6.33)
INR 1.17 ± 0.08 1.06 ± 0.08 0.01 (0.11 to 0.12)
Bleeding time 2.8 ± 1.0 3.0 ± 1.2 0.20 (0.970 to 0.78)
Factor V 91.0 ± 3.5 90.8 ± 2.9 0.16 (3.99 to 4.33)
aPTT 42.8 ± 10.2 44.3 ± 8.9 1.4 (7.63 to 6.96)
S. Createnine 0.87 ± 0.18 0.71 ± 0.37 0.16 (0.22 to 0.53)
Blood urea 20.83 ± 2.48 23.33 ± 4.23 2.50 (6.95 to 1.96)
ALT= alanine aminotransferase, PC = prothrombine concentration, INR= international normalization ratio and aPTT = activated partial
thromboplastine time.
Table 4 Complications of FENT group (n= 29) and KETR
group (n= 28).
FENT KETR P value
Nausea (%) 58.62 21.42* 0.021
Vomiting (%) 7.14 10.34 0.415
Blood loss (ml) 301.7 ± 26.4 268.3 ± 0.24 0.113
* P< 0.05 compared to the control group.
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ings regarding the synergistic effects of adding sub-standard
dose of ketorolac to opioid analgesic were they recorded a low-
er pain score in the ketorolac treatment group and also, lower
opioid consumption (20%) in both post-operative day 1 and
day 2 compared to opioid only control group [16]. Similar re-
sults was achieved by Kim and his collogues using remifentanil
and ketorolac [17].
In this work, we assessed sedation in this trial using the 6
points Ramsey sedation score [8]. Patients in KETR group
exhibited better (lower) sedation score compared to patients
in FENT group between 12 and 36 h post-operatively. The sig-
niﬁcantly lower overall daily dose of fentanyl administered in
the KETR group compared to the FENT group by 31.9% in
the ﬁrst 24 h and by 42.7 in the second 24 h could justify the
higher sedation score in the FENT group. Previous investiga-
tors had similar results with the addition of ketorolac to their
post-operative opioid based analgesia. (REF KIM) The lack of
signiﬁcant difference in the sedation score between both
groups at the end of the study (48 h) is attributed to the very
low sedation score achieved in both of them with patients
requiring less fantanyl in both groups compared to the ﬁrst 24.
NSAIDs are accused by increasing blood loss duo to
inhibition of platelet aggregation [18]. Yet, the results areconﬂicting among different subsets of NSAIDs [19]. Previous
investigators reported an increase in the bleeding tendency in
their trials using ketorolac [7,20]. Yet, in these two trials, a dif-
ferent population (pediatric) was used, the type of operation
(tonsillectomy) where the incidence of bleeding is increased
by 3.5 times in ENT surgery compared to other surgical sites
[21] and the dose of ketorolac given in both studies (1 mg kg)
were the complications of ketorolac were previously demon-
strated to be dose-dependent [22] may have participate in these
results that are contradictory to our ﬁndings in this trial were
the addition of ketorolac to IV PCA fentanyl did not induce
any signiﬁcant differences from the control group in bleeding
time, transfusion requirements or blood loss. Liver resection
results in decrease in the concentration of clothing factors
due to transient insufﬁciency of the remaining liver to synthe-
size new factors, factor consumption and operative ﬁbrinolysis
[23,24]. However, this effect is time dependant and may not be
effective during the ﬁrst 24–48 h post-operatively especially
with donor hepatectomy due to the supreme quality of the do-
nor liver documented through the extensive pre-transplant
work up in our center including liver biopsy.
The incidence of nausea in our trial was signiﬁcantly lower
in the kETR group compared to the control group. These re-
sults were in agreement with previous work on abdominal sur-
gery with reported reduction of the incidence of nausea in
ketorolac treated patients [12]. Previous studies reported an
anti-emmitc effect of ketorolac in different post-operative set-
tings [25,26].
One of the study limitations was the restriction of the cohort
to a limited age group (21–40) which is the age for acceptance
for right lobe liver donation in our program, hence, we cannot
recommend extrapolation of our ﬁndings to different age
groups. Also, the excellent quality of the donor livers may have
played a major role in the results of our study that may not be
safely achieved if applied to patients with diseased liver sub-
204 A.M. Yassen, G.E. Sayedjected to major hepatectomy. We could conclude that low dose
iv infusion Ketorolac tromethamine augmented the post-oper-
ative analgesic effect of IV PCA fentanyl without any added
morbidity to patients subjected to right lobe liver hepatectomy
for liver donation.References
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